[Peripartum cardiomyopathy].
Peripartum cardiomyopathy is a rare and potentially fatal disease with peripartum heart failure in previously healthy women. A brief review of the literature is provided with emphasis on recent data indicating that an antiangiogenic cleavage product of prolactin contributes to the molecular mechanisms underlying peripartum cardiomyopathy, and that blocking the release of prolactin with bromocriptine can ameliorate the condition.
Bretler
Ditte-Marie
DM
Gentofte Hospital, Kardiologisk Afdeling P, DK-2900 Hellerup. dimabr01@geh.regionh.dk
Jørgensen
Casper Haslund
CH
Olesen
Jonas Bjerring
JB
Gislason
Gunnar Hilmar
GH
Hansen
Peter Riis
PR
D001971:Bromocriptine / Q000627:therapeutic use; D009202:Cardiomyopathies / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D005260:Female; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D011644:Puerperal Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D012307:Risk Factors
D006727:Hormone Antagonists; D001971:Bromocriptine